Pfizer and Moderna vaccines effective against B1617 and B1618 variants

Pfizer and Moderna vaccines effective against B1617 and B1618 variants

Pfizer and Moderna vaccines effective against B1617 and B1618 variants.   A new study by American scientists found that Pfizer and Moderna’s COVID-19 vaccines are still highly effective against two variants of the COVID-19 virus strains B1617 and B1618.

This preliminary laboratory-based study was conducted by NYU Grossman School of Medicine and NYU Langone Medical Center. The study has not been published in a peer-reviewed journal.

Landau, who wrote the research report, told AFP reporters on Monday (May 17): “We found that the vaccine’s antibody is slightly weaker against the mutant strain, but it is not enough to make us think that it will have a great effect on the vaccine’s protective ability. Great negative impact.”

For the B1617 variant, the researchers found that the number of neutralizing antibodies was reduced by almost four times, while for the B1618 variant, the number of neutralizing antibodies was reduced by about three times. Neutralizing antibodies are Y-shaped proteins created by the immune system to prevent pathogens from invading cells.

Landau said: “Although some antibodies no longer work on the variant, there are still many antibodies that work on the variant.” He said that the researchers believe that there are enough antibodies to make the vaccine highly protective. He explained that this is because the overall level of the antibody is still much higher than the level of antibodies collected from people who have recovered from an early unmutated virus infection.

However, the researcher said that the possibility of new variants that are more resistant to vaccines will not be ruled out.

(source:internet, reference only)

Disclaimer of medicaltrend.org